Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk A/S : – Share repurchase programme

share with twitter share with LinkedIn share with facebook
share via e-mail
02/14/2020 | 08:32am EDT

Bagsværd, Denmark, 14 February 2020 – On 5 February 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.

Under the programme, initiated 5 February 2020, Novo Nordisk will repurchase B shares for an amount up to DKK 2.9 billion in the period from 5 February 2020 to 4 May 2020.

Since the announcement of the programme, the following transactions have been made:

 Number of
B shares
Average
purchase price
Transaction
value, DKK
5 February 2020100,000433.4643,345,975
6 February 2020110,000434.4347,787,423
7 February 2020110,000435.5547,910,128
10 February 2020110,000431.4547,460,033
11 February 2020110,000434.9147,840,285
12 February 2020110,000431.6847,484,518
13 February 2020110,000432.0147,520,611
Accumulated under the programme760,000 329,348,973

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 252,288 B shares in the period from 5 February 2020 to 13 February 2020. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 50,828,493 B shares of DKK 0.20, corresponding to 2.1% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 13 February 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 760,000 B shares at an average share price of DKK 433.35 per B share equal to a transaction value of DKK 329,348,973.

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:  
Anne Margrethe Hauge+45 4442 3450amhg@novonordisk.com
Ken Inchausti (US)+1 609 240 9429kiau@novonordisk.com
   
Investors:  
Peter Hugreffe Ankersen+45 3075 9085phak@novonordisk.com
Valdemar Borum Svarrer+45 3079 0301jvls@novonordisk.com
Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com
Mark Joseph Root+45 3079 4211mjhr@novonordisk.com
Kristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com

Company announcement No 11 / 2020

Attachment

  • CA200214_Safe_Harbour

© OMX, source OMX

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVO NORDISK A/S
04/04Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2..
GL
04/02NOVO NORDISK A/S : DTU increases Rigshospitalet's testing capacity
AQ
04/01NOVO NORDISK A/S : - Saxenda demonstrated improvements in BMI and body weight in..
AQ
03/30NOVO NORDISK A/S : - Share repurchase programme
AQ
03/27NOVO NORDISK AS : Ex-dividend day for final dividend
FA
03/26NOVO NORDISK A/S : - Articles of Association
AQ
03/26Resolutions from the Annual General Meeting of Novo Nordisk A/S
GL
03/26NOVO NORDISK A/S : Proxy Statments
CO
03/23NOVO NORDISK A/S : Disclosure of transaction data
PU
03/23NOVO NORDISK A/S : Share repurchase programme
PU
More news
Financials (DKK)
Sales 2020 130 B
EBIT 2020 55 091 M
Net income 2020 42 324 M
Finance 2020 13 373 M
Yield 2020 2,22%
P/E ratio 2020 22,6x
P/E ratio 2021 19,9x
EV / Sales2020 7,28x
EV / Sales2021 6,81x
Capitalization 958 B
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 416,13  DKK
Last Close Price 408,35  DKK
Spread / Highest target 22,4%
Spread / Average Target 1,91%
Spread / Lowest Target -29,0%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S7.93%141 503
JOHNSON & JOHNSON-8.72%345 705
ROCHE HOLDING AG2.77%277 060
MERCK & CO., INC-16.16%195 141
NOVARTIS-11.15%187 703
PFIZER, INC.-14.14%181 075